Under construction – not a live service
Sign in
Taking people in AustraliaNo phase

Adaptive Radiotherapy Study for Prostate Cancer Patients

Tests adaptive radiotherapy that adjusts daily to reduce side effects in prostate cancer patients.

Plain-language title generated from the registry record
Registry title: Prostate Adaptive Radiation Therapy

Key facts

Where
St Leonards, AustraliaSee the site

Where in Australia

  • Northern Sydney Cancer Centre/Royal North Shore HospitalSt Leonards, AustraliaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Royal North Shore Hospital
Trial code
NCT06547398
Record updated
5 February 2026
Original description
Prostate ART is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for prostate cancer patients.Read full original descriptionShow less

Prostate Adaptive Radiation Therapy

Prostate ART is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for prostate cancer patients.

Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced.

Phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2.

Part 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for prostate cancer patients.

Inclusion: - Age > 18; Biopsy proven prostate malignancy; Definitive treatment is radiotherapy to the prostate alone; ECOG performance status 0-2; Ability to understand and the willingness to sign an informed consent.

Exclusion: Hip prosthesis; Patient separation from prostate centre to skin edge > 24cm, measured on diagnostic scan-.

ClinicalTrials.gov NCT06547398